Securities code: 300199 securities abbreviation: Hybio Pharmaceutical Co.Ltd(300199) Announcement No.: 2022-019
Hybio Pharmaceutical Co.Ltd(300199)
Announcement on abnormal fluctuations in the company's stock trading
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Special tips:
1. The New Coronavirus polypeptide nasal spray drug is being developed by the company. There are also many links including COVID-19 virus and its variants, such as live poison test, pre clinical research, clinical research, pharmaceutical research and market promotion.
2. There are covid-19 preventive and therapeutic drugs in different research and development stages in the world. Many covid-19 vaccines have been put on the market in China, and many antibodies and small molecule drugs are also in different research and development stages. There is uncertainty in the market competition pattern after the new drug is put on the market;
3. Affected by the development and control of overseas epidemic situation, the choice of drug use, overseas market promotion and other factors, there is still uncertainty about whether the clinical trial application and products can be successfully approved for listing;
On January 25, 2022, the company disclosed the performance forecast for 2021. The net profit attributable to shareholders of Listed Companies in 2021 is expected to be 25-37.5 million yuan, and the net profit after deducting non recurring profits and losses is expected to be 380-430 million yuan, an increase of 31.20% - 39.20% over the same period of last year. There is no situation that should be corrected in this performance forecast. The net profit of the company in 2021 is small, and the share price decreases greatly in the short term, but the production and operation situation has not changed significantly. The company solemnly reminds investors to pay attention to the transaction risk of the secondary market, make prudent decisions and invest rationally.
1、 Abnormal fluctuations in stock trading
Hybio Pharmaceutical Co.Ltd(300199) (hereinafter referred to as "the company") shares fell by more than 30% from the closing price for three consecutive trading days (January 21, 2022, January 24, 2022 and January 25, 2022). According to the relevant provisions of the special provisions on GEM trading of Shenzhen Stock Exchange, it belongs to the situation of abnormal fluctuation of share trading.
2、 Description of the company's concern and verification
In view of the abnormal fluctuation of the company's stock trading, the board of directors of the company verified the controlling shareholders, actual controllers, all directors, supervisors and senior managers of the company through telephone and on-site inquiry. The relevant information is described as follows:
1. After verification, there is no need to correct or supplement the information disclosed by the company in the early stage;
2. After verification, the company has not found any unpublished material information that may or has had a great impact on the company's stock trading price reported by the public media recently;
3. After verification, the current production and operation of the company is normal, and the internal and external business environment has not changed significantly; 4. After verification, the controlling shareholders and actual controllers of the company do not have any major matters that should be disclosed but not disclosed by the company, or major matters in the planning stage;
5. It is verified that during the period of abnormal stock fluctuations, the controlling shareholders, actual controllers, directors, supervisors and senior managers of the company did not buy or sell stocks;
6. The company has no other circumstances in violation of the provisions on fair information disclosure;
7. Other matters to be explained:
(1) On November 12, 2021, the company held the 37th meeting of the Fourth Board of directors, The bill was passed through the "motion on technology transfer contract with the Institute of Microbiology of China Academy of Sciences". China's China Securities Regulatory Commission announced the announcement of the Hybio Pharmaceutical Co.Ltd(300199) website on New Coronavirus polypeptides nasal spray in collaboration with the Institute of Microbiology, CAS.
(2) On December 25, 2021, the third meeting of the Fifth Board of directors and the second meeting of the Fifth Board of supervisors of the company deliberated and approved the proposal on the change of accounting methods of joint-stock companies. For details, see the announcement on the change of accounting methods of joint-stock companies disclosed at the same time on the information disclosure website designated by the gem of China Securities Regulatory Commission.
(3) On December 29, 2021, the company issued the suggestive announcement on terlipressin for injection passing the conformity evaluation of generic drugs.
(4) On January 14, 2022, the company issued the suggestive announcement on the conformity evaluation of atoxiban acetate injection through generic drugs.
(5) On January 25, 2022, the company issued the performance forecast for 2021.
3、 Is there any explanation that should be disclosed but not disclosed
The board of directors confirms that the company does not have any matters that should be disclosed but not disclosed in accordance with the relevant provisions of the Listing Rules of Shenzhen Stock Exchange or the planning and intention related to such matters, and the board of directors has not been informed of the matters that should be disclosed but not disclosed in accordance with the relevant provisions of the Listing Rules of Shenzhen Stock Exchange Information that may have a great impact on the trading price of the company's shares and their derivatives.
4、 Risk tips
1. Through self-examination, the company does not violate the fair disclosure of information.
2. The New Coronavirus polypeptide nasal spray drug is being developed by the company. There are also many links including COVID-19 virus and its variants, such as live poison test, pre clinical research, clinical research, pharmaceutical research and market promotion.
3. There are covid-19 preventive and therapeutic drugs in different research and development stages in the world. Many covid-19 vaccines have been put on the market in China, and many antibodies and small molecule drugs are also in different research and development stages. There is uncertainty in the market competition pattern after the new drug is put on the market;
4. Affected by the development and control of overseas epidemic situation, the choice of drug use, overseas market promotion and other factors, there is still uncertainty about whether the clinical trial application and products can be successfully approved for listing;
5. On January 25, 2022, the company disclosed the performance forecast for 2021. The net profit attributable to shareholders of Listed Companies in 2021 is expected to be 25-37.5 million yuan, and the net profit after deducting non recurring profits and losses is expected to be 380-430 million yuan, an increase of 31.20% - 39.20% over the same period of last year. There is no situation that should be corrected in this performance forecast. The company's share price has fallen sharply in the short term, but the production and operation situation has not changed significantly. The company solemnly reminds the majority of investors to pay attention to the trading risks in the secondary market, make prudent decisions and invest rationally.
6. The information disclosure media designated by the company are securities times, China Securities News, Shanghai Securities News, securities daily and cninfo. Com. All information of the company shall be subject to the information published in the above designated media.
It is hereby announced.
Hybio Pharmaceutical Co.Ltd(300199) board of directors January 26, 2022
